A destruição funcional das vias de controle do ciclo celular constituem um evento comuns em todos os tumores humanos. Muitos estudos associam mutações em p53 com mau prognostico no tratamento do câncer. Nesse trabalho, visamos a geração e caracterização de linhagens isogênicas portando diferentes mutantes de p53 como modelo de estudo para remediação simultânea de p53 e p16 na presença de mutantes hotspots específicos. Os mutantes R175H e R248Q não geraram alterações na cinética de proliferação da linhagem H358, mas levaram a um aumento de 27,5% na eficiência de plaqueamento e, no caso de R248Q, ao dobro de eficiência na formação de colônias em suspensão. Os resultados do tratamento das linhagens isogênicas com adenovírus Adp16 e Adp53 mostraram que os mutantes não interferiram no parada do ciclo celular em G1 induzida por p16. / Alterations of the cell cycle pathway are a common event in all human tumors. Several studies have shown a correlation between hotspot mutations and an unfavorable profile for cancer therapies. Hence, this study aims the generation and characterization of isogenic cell lines, harboring p53 mutants, as model to investigate the replacement of p53 and p16 genes on these mutant H358 cell lines. Our data identified that neither p53R175H nor p53R248Q mutants accelerated cell cycle progression. However, both leads to a 27,5% increased plate efficiency while R248Q leads to a two-fold increases in the number of colonies formed in soft agar. Our data also showed that the mutants did not affect the efficiency of p16 replacement.

O melanoma maligno é uma forma de câncer com alto índice de morte devido, em parte, à falta de tratamentos eficazes e à sua tendência de formar metástases. Nosso grupo tem desenvolvido vetores virais para a transferência gênica de fatores anti-tumorais e, inicialmente, foi construído um vetor adenoviral, AdPG, no qual a expressão do transgene é controlada por p53, um supressor de tumor e fator de transcrição. Sendo que aproximadamente 90% dos casos de melanoma retêm p53 selvagem, foi proposto que isto pudesse ser utilizado como uma ferramenta para dirigir a expressão do transgene codificado pelo vetor AdPG, um mecanismo apoiado por resultados anteriores de nosso grupo. Por exemplo, a transdução de células B16 (melanoma de camundongo, p53-selvagem, deleção de p19Arf) com vetores AdPG portadores de p19Arf ou interferon-<font face=\"Symbol\">b (IFN<font face=\"Symbol\">b) resultou em morte celular maciça enquanto a transferência de apenas um destes fatores isolados não causou o mesmo efeito. O trabalho descrito aqui inclui dois avanços tecnológicos críticos em comparação com trabalhos anteriores do grupo. Primeiramente, os transgenes de interesse (eGFP, p19Arf e IFN<font face=\"Symbol\">b) foram inseridos num vetor adenoviral que apresenta o tripetídeo RGD na sua proteína fibra. Essa modificação no vetor permite a eficiente transdução de um amplo espectro de células alvos sem a dependência do receptor viral do adenovírus selvagem, CAR. Além disso, foi construído um vetor bicistrônico, que contém a combinação de ambos os genes terapêuticos, como forma de garantir a transferência dos dois fatores ao mesmo tempo para as células-alvo. A inclusão de p19Arf, um supressor de tumor e inibidor de MDM2, como um gene terapêutico deve complementar as atividades do p53 celular endógeno e, como consequência, atuar na promoção da expressão a partir do vetor e também na inibição da proliferação das células tumorais. Porém, a transferência de p19Arf sozinho acarretaria efeito somente nas células que foram transduzidas e, então, seu efeito seria limitado. Por este motivo, descreve-se, além do p19Arf, a utilização de IFN<font face=\"Symbol\">b, uma proteína secretada com funções anti-tumorais, incluindo inibição de angiogênese, indução de apoptose e ativação da resposta imunológica. A estratégia do projeto contemplou vários níveis relacionados ao mecanismo do processo de transferência, incluindo a eficiência da transdução, o mecanismo de controle da expressão dos transgenes e as atividades dos transgenes. Assim, foi proposto que a combinação de p19Arf e IFN<font face=\"Symbol\">b pudesse ser uma estratégia interessante para induzir morte no tumor primário e uma resposta imunológica contra as células metastáticas. Com este projeto, foi iniciada a construção destes novos vetores aprimorados para transferência gênica nas células de melanoma. / Malignant melanoma is a type of cancer with high death rates, in part, because of a lack of efficient treatments and its tendency to generate metastases. Our group has developed viral vectors for the gene transfer of anticancer factors and, initially, we constructed an adenoviral vector, AdPG, in which transgene expression is controlled by p53, a tumor suppressor and transcription factor. As 90% of melanoma cases maintain wild-type p53, it was proposed that this could be used as a tool to drive transgene expression encoded by the AdPG vector, as evidenced by previous studies from our group. For example, transduction of B16 cells (mouse melanoma, wild-type p53, p19Arf-null) with vectors encoding p19Arf or interferon-<font face=\"Symbol\">b (IFN<font face=\"Symbol\">b) resulted in massive death cell, while transfer of just one of these factors alone did not cause the same effect. The work described here includes two critical technologic advances in comparison with our previous work. First, transgenes of interest (eGFP, p19Arf and IFN<font face=\"Symbol\">b) were inserted into an adenoviral vector which presents the RGD tripeptide in its fiber. This vector modification allows efficient transduction in a wide range of target cells without dependence on the wild type adenovirus receptor, CAR. In addition, a bicistronic vector was constructed which contains the combination of both therapeutic genes, ensuring the transfer of both factors to the target cells at the same time. Use of p19Arf, a tumor suppressor and MDM2 inhibitor, as a therapeutic gene should complement endogenous p53 activities and, as a consequence, promote expression from the AdPG vector and inhibit tumor cell proliferation. However, p19Arf gene transfer alone should have an effect only in transduced cells and, therefore, its effect would be limited. For this reason, we describe, in addition to p19Arf, the application IFN<font face=\"Symbol\">b, a secreted protein with antitumor functions, including inhibition of angiogenesis, induction of apoptosis and activation of immunologic response. This strategy involves several mechanistic levels related with the gene transfer process, including transduction efficiency, control over transgene expression and transgene activity. Therefore, it was proposed that the combination of p19Arf and IFN<font face=\"Symbol\">b could be an interesting strategy to induce primary tumor death and an immunologic response against metastatic cells. In this project, the construction of new vectors optimized for gene transfer in melanoma cells was initiated.

Certains adénovirus humains (HAdV) comme le sérotype 3 (appartenant au sous-groupe B) sont capables de former des particules pseudo-virales composées des deux protéines impliquées dans l’entrée virale : la base du penton et la fibre (= penton). En effet, 12 pentons sont capables de s’auto-assembler de manière symétrique pour former des particules appelées dodécaèdres (Dd). Dans le présent travail, nous avons modifié et caractérisé les dodécaèdres bases (c’est à dire des Dds sans fibres) de l’HAdV3 afin d’en faire une plateforme vectorielle multi-épitopique versatile appelée ADDomer (ADenovirus Dodecamer). Pour cela, nous avons identifié des régions de la base du penton permettant l’insertion de peptides d’intérêt et créé une plateforme génétique générique permettant l’insertion facile de ceux-ci par biologie synthétique. L’insertion de séquences codant un peptide d’intérêt directement dans le gène de l’ADDomer, résulte dans son exposition de manière multivalente à la surface de la VLP du fait de la pentamérisation puis de la dodécamérisation de la base. L’ADDomer a été produit et caractérisé afin d’évaluer sa capacité à vectoriser des épitopes linéaires ou structuralement complexes. Nous avons ensuite conçu une deuxième stratégie de vectorisation, toujours basée sur l’ADDomer mais cette fois-ci en utilisant l’interaction base/fibre. Un peptide mimant la partie de la fibre de l’HAdV3 (les 20 résidus N-terminaux) interagissant avec la base du penton a été élaboré pour servir d’adaptateur formant des liaisons covalentes avec l’ADDomer.Le comportement de l’ADDomer in vivo a été étudié dans un contexte vaccinal. Pour cela, nous avons injecté l’ADDomer chez la souris afin de valider son transport vers le système lymphatique. Nous avons également démontré que l’ADDomer était capable de s’internaliser dans les monocytes et dans des cellules dendritiques dérivées de monocytes et d’induire les caractères spécifiques de maturation de ces dernières. Fort de ces résultats, nous avons généré un ADDomer vectorisant un épitope du virus Chikungunya décrit pour être la cible d’anticorps neutralisants de patients infectés par ce virus. Pour finir cette étude in vivo, nous avons évalué la capacité de l’ADDomer-TevChik à induire la réponse anti-épitopique et nous avons ainsi démontré que la façon dont l’épitope est présenté à la surface de l’ADDomer était importante pour obtenir une réponse significative. / Some human adenoviruses (HAdV) such as adenovirus derived from serotype 3 (belonging to subgroup B) are able to form virus-like particles composed of the two proteins involved in viral entry: the penton base and the fiber (= penton). Indeed, 12 pentons are able to self-assemble in a symmetrical manner to form penton dodecahedron (PtDd). In the present work, we modified and characterized the base dodecahedron (BsDd = PtDd without fiber) of HAdV3 in order to create a versatile multi-epitopic platform named ADDomer (ADenovirus Dodecamer). We have created a genetic platform allowing easy insertion of epitope(s) of interest (s) thanks to synthetic biology. The insertion of sequences encoding a peptide of interest in the ADDomer gene enable a multivalent exposure at the surface of the VLP due to the pentamerization then to the dodecamerization of the penton base. ADDomer has been produced and characterized to assess its ability to vectorize linear or structurally complex epitopes. We then designed a second vectorization strategy, still based on the ADDomer, but using the interaction penton base / fibre. A peptide mimicking the part of the Ad3 fiber interacting with the penton base (the 20 N-terminal residues) has been designed to serve as an adaptor forming covalent bonds with the ADDomer.The behavior of the ADDomer in vivo has been studied in a vaccine context. For this, we injected the ADDomer in mice to validate its transport to the lymphatic system. We have also demonstrated that ADDomer is able to internalize monocytes and dendritic cells derived from monocytes (MoDC) and induces the specific characters of MoDC maturation. Based on these results, we generated an ADDomer vectorizing an epitope of the Chikungunya virus (ADDomer TevChik) described to be the target of neutralizing antibodies of patients who have been infected by this virus. To conclude this in vivo study, we assessed the ability of ADDomer TevChik to induce the anti-epitopic response and thus demonstrated that the way the epitope is displayed on the surface of the ADDomer was important to obtain a meaningful response.

No description available.

Gene therapy is a fast growing technology that offers treatments for genetic diseases. The method is based on introducing genetic material into a patient to replace the disease-causing gene, using a vector. This report examines the potential of some viral vectors for gene therapy, to give Bio-Works Technologies a recommendation on what the future market demands. Oncolytic viruses, vaccines and gene editing are not treated in the report as a delimitation.  Viral vectors have different biological properties and require different purification methods, making them suitable for different applications in gene therapy. In the purification of the viruses it can be challenging to obtain a high purity and large-scale manufacturing. One major drawback with most purification methods is that they are not specific to just one virus, which leads to contaminants in the solution and lower purity. The viral vectors handled in the report are the adenovirus, adeno-associated virus, gammaretrovirus, lentivirus, alpharetrovirus, foamy virus, herpes simplex virus and baculovirus. These were chosen as they are relevant vectors for gene therapy and stay within the scope of the report. Lentiviral vectors (LVs) and adeno-associated viral vectors (AAVs) will dominate the gene therapy field in the coming years. This is based on the information that the use of AAVs and LVs in clinical trials have increased in recent years, while the other vectors mentioned above have slightly decreased or show no apparent change. However, challenges still remain in the purification processes. Ligands used in affinity chromatography for purification of AAVs are effective at removing most contaminants, but cannot distinguish between empty and loaded capsids, which can induce immune response when used clinically. This is the main challenge when purifying AAVs. The empty capsids can be removed with ion exchange chromatography, which results in higher purity but also lower recovery. There is no specific purifying method for LVs, therefore a lentivirus-specific affinity ligand, such as an antibody ligand, would be beneficial for the purification and manufacturing procedure.  In addition to AAVs and LVs, baculoviral vectors and foamy viral vectors show great potential in a long-term perspective but they only have been researched in preclinical studies. Moreover, herpes simplex viral vectors and adenoviral vectors show potential in cancer treatments or as vaccines rather than in augmentation gene therapy.

Previous studies have established that ozone-oxygen mixtures can be used to inactivate a variety of microorganisms including bacteria, fungi and viruses. Ozone is a potent reactive oxygen species (ROS) that rapidly decays into a variety of additional short half-life ROS which have been shown to cause oxidative damage to biological molecules. I hypothesize that controlled ozone exposure and the subsequent generation of additional ROS would reduce viral infectivity by lipid and/or protein peroxidation. A proprietary ozone-oxygen delivery system was used to inactivate a series of enveloped [herpes simplex virus type-1 strain McIntyre (HSV-1), vaccinia strain Elstree (VAC), vesicular stomatitis virus strain Indiana (VSV), and influenza A strain (H1N1) A/WS/33] and non-enveloped [human adenovirus type2 (Ad2)] viruses. Plaque reduction and suspension-infection viral antigen assays were used to determine inactivation kinetics. After ozonation, HSV-1 and VSV lost up to 6 log10 infectious particles in 15 min, while VAC and influenza A lost up to 5 log10 in 40 min and 30 min, respectively. In comparison, the non-enveloped Ad2 lost up to 5 log10 in 60 min. Increasing amounts of serum supplementation in the ozone treated virus suspensions slowed the rate of inactivation in both enveloped and non-enveloped viruses, suggesting the protective effect of serum against ozone. Lipid peroxidation was determined through a chromogenic assay for malondialdehyde (MDA), a byproduct of peroxidation events. MDA concentrations were inversely correlated with virus infectivity, as MDA concentrations elevated with virus exposure time to ozone. Transmission electron microscopy images of Ad2, HSV-1, VAC and VSV confirmed the drastic morphological changes that resulted from ozone treatment. The ROS-mediated attack compromised the integrity of the lipid envelopes and protein shells of the viruses. These data suggest that a wide range of viruses can be inactivated through use of an innovative ozone delivery system, thus validating my hypothesis.

No description available.

No description available.

Previous studies reported on the broad-spectrum antiviral function of heparin. Here we investigated the antiviral function of magnesium-modified heparin and found that modified heparin displayed a significantly enhanced antiviral function against human adenovirus (HAdV) in immortalized and primary cells. Nuclear magnetic resonance analyses revealed a conformational change of heparin when complexed with magnesium. To broadly explore this discovery, we tested the antiviral function of modified heparin against herpes simplex virus type 1 (HSV-1) and found that the replication of HSV-1 was even further decreased compared to aciclovir. Moreover, we investigated the antiviral effect against the new severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and measured a 55-fold decreased viral load in the supernatant of infected cells associated with a 38-fold decrease in virus growth. The advantage of our modified heparin is an increased antiviral effect compared to regular heparin.

L'interférence ARN est un processus biologique permettant la dégradation d'un ARN messager par un ARN double brin de courte taille spécifique de cet ARNm. Elle a un potentiel d'application en thérapie antivirale pour peu que les ARN interférents (ARNi) soient délivrés efficacement in vivo. Dans le genre Morbillivirus, on trouve des pathogènes importants en santé publique et vétérinaire tels que le virus de la rougeole et les virus de la peste des petits ruminants (PPR) et de la peste bovine. Il n'existe aucun traitement contre les infections à morbillivirus. L'objectif de ce travail était d'évaluer la possibilité d'administrer in vivo un ARNi actif contre le virus PPR in vitro. Une formulation basée sur des liposomes complexés avec des ARNi ou un adénovirus non réplicatif exprimant des ARN courts en tête d'épingle (shARN) ont été testés chez des chèvres dans un modèle d'épreuve infectieuse avec une souche virulente de PPR. Les différences observées n'étaient cependant pas significatives au plan statistique. Pour améliorer la délivrance par vecteur viral, nous avons comparé un autre vecteur de type baculovirus qui s'est avéré plus efficace in vitro que l'adénovirus précédent. Par ailleurs, nous avons testés in vitro également deux peptides capables de pénétrer dans les cellules. L'un d'entre eux, le Perfect 6 (PF6) a presque complètement inhibé l'expression du gène de la nucléoprotéine par le virus PPR. En revanche, l'autre (PF14) a été moins efficace mais a relativement mieux résisté à l'inhibition de son activité par la présence de fortes concentrations de sérum dans le milieu. Dans le but d'évaluer in vivo ces nouveaux systèmes de délivrance en s'affranchissant du modèle chèvre lourd et couteux à mettre en œuvre, nous avons initié une stratégie de mise au point d'un modèle non infectieux de suivi dynamique de l'interférence ARN chez la souris par imagerie in vivo. Dans ce travail, nous montrons qu'il est possible de mesurer et de standardiser l'expression d'un gène rapporteur comprenant une séquence du virus PPRV et ensuite de quantifier le niveau de dérégulation de l'expression induit par un ARNi dirigé contre le virus PPR. Après calibration, ce modèle est désormais pour tester différents systèmes de délivrance de siRNA chez la souris / RNA interference (RNAi) is the process of mRNA degradation that is induced by double-stranded RNA in a sequence-specific manner. RNAi has a potential of developing into an effective and specific antiviral therapy if small interfering RNAs (siRNAs) can be efficiently delivered in vivo. Morbillivirus genus includes important pathogens of humans and animals, which include measles virus, peste des petits ruminants virus (PPRV) and rinderpest virus. No treatment exists for morbillivirus diseases. The aim of this work was the in vivo delivery of siRNA against PPRV infection. The delivery of siRNA by a liposome and short hairpin RNA (shRNA) by means of a replication deficient adenovirus was tested in goats which were later challenged with PPRV. However, significant therapeutic effects were not obtained. To find more efficient vectors, the PPRV inhibition efficiency of recombinant replication deficient adenovirus and a baculovirus expressing shRNA against nucleoprotein of PPRV were compared in vitro. The baculoviral vector was found to be more efficient. Similarly, two cell penetrating peptides (CPPs) were also compared and PepFect6 (PF6) could deliver siRNA NPPRV1 effectively in vitro resulting in an almost complete inhibition of N gene expression by PPRV. Another CPP, the PF14 though with lower transfection efficiency in vitro, was found to be relatively serum resistant compared to PF6. A small animal model for PPRV infection does not exist. Due to economic, ethical, and biosecurity issues involved with use of small ruminants, a strategy based on the use of a non-infectious mouse model and a dynamic follow up of siRNA treatment by live imaging was developed. We show in this work that it is possible to measure and standardize the expression of a bioluminescent reporter gene containing a PPRV sequence and thus, to quantify a down-regulation of such gene by siRNA against PPRV. After some calibration, siRNA delivery can now be tested in this mouse model for comparing various delivery vectors in vivo.